Drug Trial Radar · NCT07013747
Study to Evaluate Safety, Efficacy and Immunogenicity of Acne mRNA Vaccine in Participants With Mild Acne
Last checked: Nov 20, 2026Latest source record: Jul 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
228
Planned (sponsor's estimate)
Start
Jul 3, 2025
Primary completion
Jun 19, 2029
Study completion Mar 13, 2030
Sponsor
- Lead sponsor
- Sanofi Pasteur, a Sanofi CompanySanofi (SNY)
- Sponsor type
- Industry
- First posted
- Jun 10, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 45 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of the VBE00009 study is to evaluate the safety, efficacy and immunogenicity of 2 administrations of the Acne mRNA vaccine candidate at single dose level in participants aged 18 to 45 years with mild acne. This study will consist of a Core Study followed by an optional Long-Term Extension (LTE). Core Study will include a Sentinel Cohort and a Main Cohort, with the Sentinel Cohort assessing the safety in a stepwise manner. If the participants consent to the LTE, they will be followed up for an additional 30 months after the last planned visit in the Core Study, to assess the long term effects of the vaccine.
Conditions
- Acne
Interventions
Acne mRNA vaccineBiological
Pharmaceutical form: suspension for injection Route of administration: intramuscular
PlaceboOther
Pharmaceutical form: liquid solution for injection Route of administration: intramuscular
Primary outcomes
What the sponsor says the trial is designed to measure.
- Core Study - Sentinel Cohort Arm 1 and 2: Number of participants with unsolicited systemic adverse events (AEs)Time frame: In 30 minutes after each administration
- Core Study - Sentinel Cohort Arm 1 and 2: Number of participants with solicited injection site and systemic reactionsTime frame: Up to 7 days after each administration
- Core Study - Sentinel Cohort Arm 1 and 2: Number of participants with unsolicited AEs reportedTime frame: Up to 28 days after each administration
- Core Study - Sentinel Cohort Arm 1 and 2: Number of participants with medically attended adverse events (MAAEs)Time frame: Up to 6 months after each administration
- Core Study - Sentinel Cohort Arm 1 and 2: Number of participants with AEs of special interest (AESIs)Time frame: Up to 6 months after each administration
- Core Study - Sentinel Cohort Arm 1 and 2: Number of participants with serious AEs (SAEs)Time frame: Up to 6 months after each administration
- Core Study - Sentinel Cohort Arm 1 and 2: Number of participants with out-of-range biological test resultsTime frame: Through 7 days after administration (Day 08)
- Core Study - Main Cohort Arm 1 and 2: Percentage change from baseline (Day 01) in the number of inflammatory acne lesions on faceTime frame: At 2 months post last administration
- Core Study - Main Cohort Arm 1 and 2: Percentage change from baseline (Day 01) in the number of non-inflammatory acne lesions on faceTime frame: At 2 months post last administration
- Long-Term Extension - Sentinel and Main Cohort Arm 1 and 2: Number of participants with serious adverse events (SAEs) and adverse events of special interest (AESIs)Time frame: Up to 38 months after first administration
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
Encino Research Center- Site Number : 8400008
Encino, California · Recruiting
Moore Clinical Research - Brandon- Site Number : 8400007
Brandon, Florida · Recruiting
Encore Research Group-Jacksonville Center for Clinical Research- Site Number : 8400006
Jacksonville, Florida · Recruiting
DelRicht Research- Site Number : 8400003
New Orleans, Louisiana · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.